The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 357:1559-1561 October 11, 2007 Number 15
NextNext

ERCC1-Specific Immunostaining in Non–Small-Cell Lung Cancer

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Supplementary Material
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-PubMed Citation
To the Editor: In their letter to the editor, Niedernhofer et al. (June 14 issue)1 have doubts about the specificity of the monoclonal mouse antibody 8F1, which is used to detect the excision repair cross-complementation group 1 (ERCC1) protein. These doubts are important to reconcile, because two studies have reported that high levels of ERCC1 expression, as detected by means of immunohistochemical staining of primary tumors with the use of the 8F1 monoclonal antibody, are associated with a good prognosis in non–small-cell lung cancer yet negatively affect the response to chemotherapeutic agents.2,3 Hence, the expression level of the epitope recognized . . . [Full Text of this Article]



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.